Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.67 |
| ▸ | CTSB | P07858 | 5/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609791 | 1.00 | APP (0.67) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL1171573 | 0.84 | APP (0.74) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL1171571 | 0.84 | APP (0.74) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL15238997 | 0.84 | APP (0.74) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL608124 | 0.82 | BACE1 (0.58) | APPCTSBCAPN1MAPTMEN1 | |
| SCHEMBL608125 | 0.82 | BACE1 (0.58) | APPCTSBCAPN1MAPTMEN1 | |
| SCHEMBL9234919 | 0.80 | APP (1.00) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL28401541 | 0.80 | APP (0.77) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL9234911 | 0.80 | APP (1.00) | APPCTSBCAPN1CTSLTDP1 | |
| SCHEMBL28399757 | 0.80 | APP (0.77) | APPCTSBCAPN1CTSLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | disclosed |
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3038621-B1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RES INSTITUTE (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3038621-A2 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | Human Biomolecular Research Institute (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | disclosed |
| WO-2014146039-A2 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010068935-A2 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068935-A2 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20090263492-A1 | Diagnostic Methods and Genetic Markers for Alzheimer Disease | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2009-10-22 | — | — | US | disclosed |
| WO-2008048410-A9 | DIAGNOSTIC METHODS AND GENETIC MARKERS FOR ALZHEIMER DISEASE | HUMAN BIOMOLECULAR RES INST (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008048410-A2 | DIAGNOSTIC METHODS AND GENETIC MARKERS FOR ALZHEIMER DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | APP 2335/4885CTSB 439/4885CAPN1 2771/4885 |
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | APP 1990/4885CTSB 364/4885CAPN1 3054/4885 |
| US-20090263492-A1 | Diagnostic Methods and Genetic Markers for Alzheimer Disease | CHAT, SLC18A3, GAP43 | APP 40/4885CTSB 787/4885CAPN1 2488/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | APP 1990/4885CTSB 364/4885CAPN1 3054/4885 |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | APP 2649/4885CTSB 513/4885CAPN1 2072/4885 |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | L1CAM, LY96, GMFG | APP 730/4885CTSB 301/4885CAPN1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.